Outcomes of patients not achieving primary endpoint from an ibalizumab Phase III trial

被引：0
|
作者：
DeJesus, E. [1 ]
Emu, B. [2 ]
Weinheimer, S. [3 ]
Cohen, Z. [4 ]
Cash, B. [5 ]
Lewis, S. [3 ]
机构：
[1] Orlando Immunol Ctr, Infect Dis, Orlando, FL USA
[2] Yale Sch Med, Infect Dis, New Haven, CT USA
[3] TaiMed Biol, HIV, Irvine, CA USA
[4] Theratechnologies, HIV, Montreal, PQ, Canada
[5] Syneos Hlth, HIV, Somerset, NJ USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P064
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Port Delivery System with ranibizumab (PDS) met primary endpoint and key secondary outcomes with > 75% of patients preferring PDS treatment in phase 3 Pavilion trial for diabetic retinopathy (DR)
    Latkany, Paul
    Regillo, Carl
    Wykoff, Charles C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy
    Malhotra, Varun
    Howard, Dena
    Santhanakrishnan, Anjana
    Wetzel-Smith, Monica
    Quezada-Ruiz, Carlos
    Pieramici, Dante Joseph
    Latkany, Paul
    Regillo, Carl
    Wykoff, Charles C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy
    Malhotra, Varun
    Howard, Dena
    Santhanakrishnan, Anjana
    Wetzel-Smith, Monica
    Quezada-Ruiz, Carlos
    Pieramici, Dante Joseph
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [42] Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial
    Amdal, Cecilie Delphin
    Jacobsen, Anne-Birgitte
    Sandstad, Berit
    Warloe, Trond
    Bjordal, Kristin
    RADIOTHERAPY AND ONCOLOGY, 2013, 107 (03) : 428 - 433
  • [43] Closeout of four phase II vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial
    Tavel, JA
    Fosdick, L
    CONTROLLED CLINICAL TRIALS, 2001, 22 (01): : 42 - 48
  • [44] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
    Strand, Vibeke
    Gossec, Laure
    Proudfoot, Clare W. J.
    Chen, Chieh-I
    Reaney, Matthew
    Guillonneau, Sophie
    Kimura, Toshio
    van Adelsberg, Janet
    Lin, Yong
    Mangan, Erin K.
    van Hoogstraten, Hubert
    Burmester, Gerd R.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [45] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
    Vibeke Strand
    Laure Gossec
    Clare W. J. Proudfoot
    Chieh-I Chen
    Matthew Reaney
    Sophie Guillonneau
    Toshio Kimura
    Janet van Adelsberg
    Yong Lin
    Erin K. Mangan
    Hubert van Hoogstraten
    Gerd R. Burmester
    Arthritis Research & Therapy, 20
  • [46] Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial
    Mei, Heng
    Liu, Xiaofan
    Li, Yan
    Zhou, Hu
    Feng, Ying
    Gao, Guangxun
    Cheng, Peng
    Huang, Ruibin
    Yang, Linhua
    Hu, Jianda
    Hou, Ming
    Yao, Yazhou
    Liu, Li
    Wang, Yi
    Wu, Depei
    Shen, Xuliang
    Jin, Jie
    Luo, Jianmin
    Zeng, Yun
    Zhou, Xin
    Xia, Ruixiang
    Jiang, Zhongxing
    Bai, Yuansong
    Niu, Ting
    Yang, Renchi
    Hu, Yu
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2273 - 2281
  • [47] Primary Biliary Cholangitis: Elafibranor successfully completes Phase III Trial
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (08): : 1190 - 1191
  • [48] 'SBRT and the Boost', a love story: primary endpoint analysis of the phase II hypo-FLAME trial
    Draulans, C.
    Van der Heide, U. A.
    Haustermans, K.
    Pos, F. J.
    van Zyp, J. Van der Voort
    De Boer, H.
    Groen, V.
    Monninkhof, E. M.
    Smeenk, R. J.
    Kunze-Busch, M.
    Depuydt, T.
    De Roover, R.
    Isebaert, S.
    Kerkmeijer, L. G. W.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S104 - S105
  • [49] Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003
    Buyyounouski, M. K.
    Pugh, S.
    Chen, R. C.
    Mann, M.
    Kudchadker, R.
    Konski, A. A.
    Mian, O. Y.
    Michalski, J. M.
    Vigneault, E.
    Valicenti, R. K.
    Barkati, M.
    Lawton, C. A. F.
    Potters, L.
    Monitto, D. C.
    Kittel, J.
    Schroeder, T. M.
    Hannan, R.
    Duncan, C. E.
    Rodgers, J.
    Sandler, H. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S2 - S3
  • [50] Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).
    Niazi, Tamim
    Nabid, Abdenour
    Bettahar, Redouane
    Vincent, Linda S.
    Martin, Andre-Guy
    Jolicoeur, Marjory
    Yassa, Michael
    Barkati, Maroie
    Igidbashian, Levon
    Bahoric, Boris
    Archambault, Robert
    Villeneuve, Hugo
    Tsui, James M.
    Mohiuddin, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345